Metabolic Disorders Program
Metabolic Disorders
Pre-clinicalActive
Key Facts
About Seragon Biosciences
Seragon Biosciences is a private, pre-revenue biotech firm leveraging advanced AI and gene therapy platforms to target aging, metabolic disorders, and immunology. The company's core technologies include the GenomeScore™ AI platform for measuring aging and a hybrid gene therapy platform for efficient gene delivery. Operating in the high-growth longevity and gene therapy sectors, Seragon appears to be in a pre-clinical or discovery-stage, building its scientific foundation and seeking partnerships to advance its research programs.
View full company profileTherapeutic Areas
Other Metabolic Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Novel GLP-1 Receptor Agonist | lupin | Pre-clinical/Clinical |
| Undisclosed Metabolic Program | Kallyope | Discovery |
| PPARγ Program | Micar Innovation | Discovery |
| Pancreas-Targeting Capsids | rAAVen Therapeutics | Pre-clinical |
| IVL-001 | InVirtuoLabs | Discovery |
| AmorphOX GLP-1 | Orexo | Preclinical |
| Amylin Program | Orion Biotechnology | Discovery |
| Not specifically disclosed on public website | Taisho Pharmaceutical | Various |
| TLC590 | Taiwan Liposome Company | Phase 2 |